Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Ionis Pharmaceuticals, Inc. operates as a biotechnology company. The Company researches in RNA-targeted drug discovery and development that focuses on drugs for patients who have unmet medical needs. Ionis Pharmaceuticals serves customers in the United States.
Website: ionispharma.com


  • Good financial results growth rate 100.0% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (-0.4%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield -0.3% (LTM)
  • Share price is 28.4% higher than minimum and 38.8% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (500.0x vs 30.0x)
  • For the last 3 months insiders bought company shares on $0.2 mln (0.004% of cap.)

Key Financials (Download financials)

Ticker: IONS
Share price, USD:  (0.0%)32.75
year average price 38.06  


year start price 39.08 2024-05-10

max close price 51.86 2024-07-25

min close price 25.51 2025-04-08

current price 32.75 2025-05-09
Common stocks: 141 798 003

Dividend Yield:  0.0%
EV / Sales: 5.4x
Margin (EBITDA LTM / Revenue): -62.8%

Target EV / EBITDA (hist percentile): 30.0x
Express share price potential:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 4 644
Net Debt ($m): -791
EV (Enterprise Value): 3 853
EBITDA LTM (млн $): -451
Price to Book: 7.1x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-05-01zacks.com

Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View

2025-04-22seekingalpha.com

Ionis: Potentially A Great Time To Buy Ahead Of Q1 Earnings (Upgrade)

2025-04-03businesswire.com

Ionis to host expert panel discussion on sHTG

2025-03-31businesswire.com

Ionis to present at upcoming investor conferences

2025-03-27zacks.com

IONS Out-Licenses ex-U.S. Rights for Rare Disease Drug Tryngolza to Sobi

2025-03-21zacks.com

Why Is Ionis Pharmaceuticals (IONS) Up 0.1% Since Last Earnings Report?

2025-03-11businesswire.com

Ono Enters into License Agreement with Ionis Pharmaceuticals for Sapablursen for the Treatment of Polycythemia Vera

2025-02-20zacks.com

Ionis' Q4 Earnings and Sales Beat Estimates, Tryngolza Launch in Focus

2025-02-19seekingalpha.com

Ionis Pharmaceuticals, Inc. (IONS) Q4 2024 Earnings Call Transcript

2025-02-19seekingalpha.com

Ionis Pharmaceuticals Reports Strong Q4 Earnings After Recent FDA Approval
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol IONS IONS IONS IONS IONS IONS IONS IONS IONS
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 874 015 874 015 874 015 874 015 874 015 874 015 874 015 874 015 874 015
fillingDate 2024-11-06 2024-08-01 2024-03-31 2024-02-21 2023-11-02 2023-08-09 2023-05-03 2023-02-22 2022-11-09
acceptedDate 2024-11-06 16:06:54 2024-08-01 16:57:19 2024-03-29 20:00:00 2024-02-21 16:38:27 2023-11-02 14:43:27 2023-08-09 13:50:14 2023-05-03 16:28:20 2023-02-22 16:39:54 2022-11-09 14:38:31
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 134M 225M 119M 325M 144M 188M 131M 152M 160M
costOfRevenue 1M 10M 8M 3M 2M 3M 1 000 000 4M 2M
grossProfit 133M 216M 112M 321M 142M 185M 130M 148M 158M
grossProfitRatio 0.992 0.957 0.935 0.991 0.986 0.984 0.992 0.974 0.988
researchAndDevelopmentExpenses 220M 222M 214M 257M 215M 230M 198M 308M 87M
generalAndAdministrativeExpenses 62M 0 53M 71M 70M 46M 46M 102M 34M
sellingAndMarketingExpenses 0 0 -6M 0 0 -100 000 484 000 400 000 -400 000
sellingGeneralAndAdministrativeExpenses 62M 60M 47M 71M 70M 46M 46M 48M 34M
otherExpenses 0 610 000 277 000 399 000 20M 32M 17M 14M 96M
operatingExpenses 281M 282M 261M 328M 285M 276M 244M 356M 217M
costAndExpenses 282M 291M 269M 331M 287M 279M 245M 360M 219M
interestIncome 2M 0 49 000 3M 24M 0 0 0 0
interestExpense 21M 23M 21M 21M 18M 18M 16M 6M 2M
depreciationAndAmortization 24M 6M 6M 43 812 20M 6M 17M -150M 14M
ebitda -125M -38M -144M -2M -123M -59M -97M -358M -45M
ebitdaratio -0.933 -0.269 -1.204 -0.005 -0.854 -0.314 -0.74 -2.355 -0.278
operatingIncome -149M -66M -150M -6M -143M -91M -114M -208M -59M
operatingIncomeRatio -1.109 -0.293 -1.251 -0.019 -0.993 -0.484 -0.87 -1.368 -0.367
totalOtherIncomeExpensesNet 5M -110 000 7M 26M 20M 32M 1 000 000 164M 12M
incomeBeforeTax -144M -66M -143M -3M -141M -77M -113M -44M -47M
incomeBeforeTaxRatio -1.075 -0.294 -1.194 -0.009 -0.979 -0.41 -0.863 -0.289 -0.294
incomeTaxExpense -4M 64 000 75 000 6M 6M 8M 11M 8M 283 000
netIncome -140M -66M -143M -9M -147M -85M -124M -52M -47M
netIncomeRatio -1.048 -0.294 -1.195 -0.029 -1.021 -0.452 -0.947 -0.342 -0.296
eps -0.95 -0.45 -0.98 -0.064 -1.03 -0.59 -0.87 -0.37 -0.33
epsdiluted -0.95 -0.45 -0.98 -0.064 -1.03 -0.59 -0.87 -0.37 -0.33
weightedAverageShsOut 149M 146M 146M 144M 143M 143M 143M 142M 142M
weightedAverageShsOutDil 149M 146M 146M 144M 143M 143M 143M 142M 142M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol IONS IONS IONS IONS IONS IONS IONS IONS IONS
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 874 015 874 015 874 015 874 015 874 015 874 015 874 015 874 015 874 015
fillingDate 2024-11-06 2024-08-01 2024-03-31 2024-02-21 2023-11-02 2023-08-09 2023-05-03 2023-02-22 2022-11-09
acceptedDate 2024-11-06 16:06:54 2024-08-01 16:57:19 2024-03-29 20:00:00 2024-02-21 16:38:27 2023-11-02 14:43:27 2023-08-09 13:50:14 2023-05-03 16:28:20 2023-02-22 16:39:54 2022-11-09 14:38:31
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 335M 294M 349M 399M 352M 425M 309M 1 987M 1 982M
shortTermInvestments 2 149M 1 785M 1 857M 1 932M 1 884M 1 961M 2 038M 1 710M 1 667M
cashAndShortTermInvestments 2 483M 2 079M 2 206M 2 331M 2 236M 2 385M 2 347M 1 987M 3 649M
netReceivables 18M 27M 5M 98M 142M 28M 14M 26M 7M
inventory 28M 29M 30M 28M 26M 26M 22M 22M 21M
otherCurrentAssets 184M 195M 174M 184M 207M 203M 182M 190M -1 687M
totalCurrentAssets 2 714M 2 329M 2 416M 2 642M 2 585M 2 616M 2 543M 2 203M 1 982M
propertyPlantEquipmentNet 247M 243M 242M 243M 245M 269M 264M 256M 181M
goodwill 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 30M
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 30M
longTermInvestments 0 41M 43M 43M 43M 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 120M 78M 63M 62M 61M 86M 78M 75M -30M
totalNonCurrentAssets 367M 362M 348M 348M 349M 355M 342M 331M 181M
otherAssets 0 0 1 0 0 0 0 0 259M
totalAssets 3 081M 2 691M 2 764M 2 990M 2 934M 2 971M 2 885M 2 534M 2 422M
accountPayables 9M 9M 13M 26M 6M 24M 10M 18M 21M
shortTermDebt 44M 44M 44M 53M 31M 25M 0 8M 5M
taxPayables 41 000 284 000 2M 2M 31M 25M 17M 6M 16 000
deferredRevenue 76M 94M 130M 151M 205M 96M 92M 91M 100M
otherCurrentLiabilities 175M 158M 140M 218M 675M 653M 662M 196M -26M
totalCurrentLiabilities 305M 306M 328M 448M 917M 798M 764M 312M 100M
longTermDebt 1 402M 1 933M 1 756M 1 400M 1 404M 1 474M 1 361M 1 345M 1 249M
deferredRevenueNonCurrent 0 189M 215M 241M 249M 254M 273M 288M 295M
deferredTaxLiabilitiesNonCurrent 0 -1 727M -356M 0 0 0 -505M 0 0
otherNonCurrentLiabilities 712M 0 525M 514M 49M 17M 505M 16M 1 602M
totalNonCurrentLiabilities 2 114M 2 121M 2 140M 2 155M 1 702M 1 745M 1 634M 1 649M 1 728M
otherLiabilities 0 0 1 0 0 0 0 0 0
capitalLeaseObligations 168M 166M 169M 171M 173M 175M 177M 178M 84M
totalLiabilities 2 419M 2 427M 2 467M 2 603M 2 619M 2 543M 2 398M 1 961M 1 828M
preferredStock 0 2 040M 0 33M 0 0 0 0 0
commonStock 158 000 146 000 146 000 144 000 143 000 143 000 143 000 142 000 142 000
retainedEarnings -2 145M -2 005M -1 939M -1 796M -1 787M -1 639M -1 554M -1 430M -1 272M
accumulatedOtherComprehensiveIncomeLoss -24M -35M -35M -33M -46M -51M -49M -57M -63M
othertotalStockholdersEquity 2 832M 2 303M 2 270M 2 182M 2 148M 2 118M 2 090M 2 060M 1 929M
totalStockholdersEquity 662M 264M 297M 387M 315M 428M 487M 573M 594M
totalEquity 662M 264M 297M 387M 315M 428M 487M 573M 594M
totalLiabilitiesAndStockholdersEquity 3 081M 2 691M 2 764M 2 990M 2 934M 2 971M 2 885M 2 534M 2 422M
minorityInterest 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 3 081M 2 691M 2 764M 2 990M 2 934M 2 971M 2 885M 2 534M 2 422M
totalInvestments 2 149M 1 826M 1 900M 1 981M 1 884M 1 961M 2 038M 1 710M 1 667M
totalDebt 1 447M 1 977M 1 969M 1 454M 1 404M 1 474M 1 361M 1 345M 1 254M
netDebt 1 112M 1 683M 1 620M 1 054M 1 052M 1 049M 1 052M -642M -728M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol IONS IONS IONS IONS IONS IONS IONS IONS IONS
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 874 015 874 015 874 015 874 015 874 015 874 015 874 015 874 015 874 015
fillingDate 2024-11-06 2024-08-01 2024-03-31 2024-02-21 2023-11-02 2023-08-09 2023-05-03 2023-02-22 2022-11-09
acceptedDate 2024-11-06 16:06:54 2024-08-01 16:57:19 2024-03-29 20:00:00 2024-02-21 16:38:27 2023-11-02 14:43:27 2023-08-09 13:50:14 2023-05-03 16:28:20 2023-02-22 16:39:54 2022-11-09 14:38:31
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -140M -66M -143M -9M -147M -85M -124M -52M 18M
depreciationAndAmortization 4M 6M 6M 6M 6M 6M 6M 7M 22M
deferredIncomeTax 0 0 0 -5M 6M -19M 0 0 0
stockBasedCompensation 32M 31M 31M 26M 26M 27M 27M 26M 75M
changeInWorkingCapital 140M -94M -46M 13M -4M -32M -55M -31M -18M
accountsReceivables 9M -22M 93M 45M -94M -41M 0 0 0
inventory 271 000 2M -2M -3M -96 000 -3M -167 000 -1M 4M
accountsPayables -2M -3M -14M 21M -18M 16M -10M -5M 6M
otherWorkingCapital 132M -70M -122M -50M 108M -3M -45M -25M -28M
otherNonCashItems -150M 4M -33M 3M 4M 6M 13M -150M -171M
netCashProvidedByOperatingActivities -115M -120M -150M 33M -109M -97M -134M -200M -74M
investmentsInPropertyPlantAndEquipment 6M -20M -6M 819 000 -3M -13M -12M -5M 3M
acquisitionsNet 0 0 0 27M 1M 1M 1M 0 0
purchasesOfInvestments -715M -285M -519M -418M -421M -244M -688M -262M -1 223M
salesMaturitiesOfInvestments 371M 368M 601M 391M 493M 327M 374M 225M 764M
otherInvestingActivites -3M 0 81M -28M -1M -1M -1M 254M -4M
netCashUsedForInvestingActivites -341M 62M 76M -27M 69M 70M -326M 212M -474M
debtRepayment -48 000 -39 000 -39 000 -38 000 -68M -420M -39 000 -51M -89 000
commonStockIssued 496M 3M 24M 41M 4M 2M 3M 343 000 3M
commonStockRepurchased 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 496M 0 24M 41M 32M 561M 490M -765 000 -7M
netCashUsedProvidedByFinancingActivities 496M 3M 24M 41M -32M 144M 492M -51M -4M
effectOfForexChangesOnCash 350 000 -23 000 -114 000 330 000 -152 000 70 000 104 000 546 000 -963 846
netChangeInCash 41M -55M -50M 47M -73M 116M 33M -39M -228M
cashAtEndOfPeriod 335M 294M 349M 399M 352M 425M 309M 276M 315M
cashAtBeginningOfPeriod 294M 349M 399M 352M 425M 309M 276M 315M 543M
operatingCashFlow -115M -120M -150M 33M -109M -97M -134M -200M -74M
capitalExpenditure 6M -20M -6M 819 000 -3M -13M -12M -5M 3M
freeCashFlow -111M -140M -156M 34M -112M -110M -146M -205M -71M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link

Earning call transcript

2024 q3
2024-11-06 ET (fiscal 2024 q3)
2024 q2
2024-08-01 ET (fiscal 2024 q2)
2024 q1
2024-05-07 ET (fiscal 2024 q1)
2023 q4
2024-02-21 ET (fiscal 2023 q4)
2023 q3
2023-11-02 ET (fiscal 2023 q3)
2023 q2
2023-08-09 ET (fiscal 2023 q2)
2023 q1
2023-05-03 ET (fiscal 2023 q1)
2022 q4
2023-02-22 ET (fiscal 2022 q4)
2022 q3
2022-11-09 ET (fiscal 2022 q3)
2022 q2
2022-08-09 ET (fiscal 2022 q2)
2022 q1
2022-05-04 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-11-07 12:05 ET
Ionis to present at upcoming investor conferences
2024-11-06 12:01 ET
Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome
2024-11-06 12:00 ET
Ionis reports third quarter 2024 financial results
2024-11-04 14:44 ET
Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE
2024-10-23 11:05 ET
Ionis to hold third quarter 2024 financial results webcast
2024-10-03 11:00 ET
New positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
2024-10-01 11:00 ET
Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease
2024-09-10 01:10 ET
Ionis announces pricing of $500.3 million public offering
2024-09-09 20:20 ET
Ionis announces proposed public offering of common stock
2024-08-28 11:05 ET
Ionis to present at upcoming investor conferences
2024-08-01 11:00 ET
Ionis reports second quarter 2024 financial results
2024-07-22 11:00 ET
Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome
2024-07-19 12:24 ET
Ionis to hold second quarter 2024 financial results webcast
2024-07-18 11:00 ET
Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease
2024-07-08 11:05 ET
Ionis announces webcast to report HALOS study results for ION582 in Angelman syndrome
2024-06-25 10:55 ET
Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed
2024-06-18 11:00 ET
Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema
2024-06-17 20:09 ET
Ionis to present at TD Cowen Genetic Medicines & RNA Summit
2024-05-31 11:00 ET
Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema
2024-05-28 11:00 ET
Ionis to hold donidalorsen Phase 3 data webcast
2024-05-23 11:00 ET
New data from the Phase 3 NEURO-TTRansform study evaluating WAINUA™ (eplontersen) to be presented at the 2024 International Symposium on Amyloidosis (ISA)
2024-05-16 11:00 ET
Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome
2024-05-15 11:05 ET
Ionis to host 2024 virtual Annual Meeting of Stockholders
2024-05-07 11:00 ET
Ionis reports first quarter 2024 financial results
2024-04-25 11:00 ET
Ionis Publishes 2023 Corporate Responsibility Report
2024-04-23 11:05 ET
Ionis to hold first quarter 2024 financial results webcast
2024-04-07 13:48 ET
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
2024-04-01 11:05 ET
Ionis to present at upcoming investor conferences
2024-03-28 11:05 ET
Ionis to hold olezarsen Phase 3 data webcast
2024-03-25 12:18 ET
Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting
2024-03-13 11:00 ET
Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH
2024-02-29 14:05 ET
Ionis announces new chief global product strategy officer to lead next phase of commercial growth
2024-02-28 12:05 ET
Ionis to present at upcoming investor conferences
2024-02-21 12:00 ET
Ionis reports fourth quarter and full year 2023 financial results
2024-02-15 12:00 ET
Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome
2024-02-08 12:00 ET
Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy
2024-02-07 12:05 ET
Ionis to hold fourth quarter and full year 2023 financial results webcast
2024-01-30 13:00 ET
Vect-Horus Enters Exclusive License Agreement with Ionis Pharmaceuticals to Advance Systemic Delivery of RNA-Targeted Medicines for Neurological Diseases
2024-01-22 12:00 ET
Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema
2024-01-08 12:03 ET
Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases
2023-12-21 23:55 ET
WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis
2023-12-20 12:05 ET
Ionis to present at 42nd Annual J.P. Morgan Healthcare Conference
2023-12-18 21:01 ET
Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema
2023-12-14 21:05 ET
Ionis announces the appointment of Michael Yang to Board of Directors
2023-11-11 16:30 ET
Ionis shares positive clinical update from ongoing trial of ION582 for Angelman syndrome
2023-11-09 17:42 ET
Ionis presents positive two-year results from the Phase 2 open label extension study of donidalorsen in patients with hereditary angioedema
2023-11-03 11:05 ET
Ionis to present at upcoming investor conferences
2023-11-02 11:00 ET
Ionis reports third quarter 2023 financial results
2023-10-19 11:05 ET
Ionis to hold third quarter 2023 financial results webcast
2023-10-04 11:00 ET
Ionis shares significant business and pipeline progress at Innovation Day, highlighting strength of capabilities from research and technology through commercialization
2023-09-28 16:02 ET
Eplontersen Phase 3 results published in JAMA show consistent and sustained benefit
2023-09-27 11:00 ET
Ionis enters agreement with Roche for two novel RNA-targeted programs for Alzheimer's disease and Huntington's disease
2023-09-26 11:00 ET
Ionis announces positive olezarsen topline results from Phase 3 study in people with familial chylomicronemia syndrome
2023-09-12 11:05 ET
Ionis to host investor and analyst day event
2023-08-30 11:05 ET
Ionis to present at upcoming investor conferences
2023-08-09 11:00 ET
Ionis reports second quarter 2023 financial results
2023-08-03 11:05 ET
Ionis enters collaboration to advance next generation program targeting Lp(a) for cardiovascular disease
2023-07-31 11:05 ET
Ionis completes enrollment in landmark Phase 3 CARDIO-TTRansform study in patients with TTR-mediated amyloid cardiomyopathy
2023-07-28 11:05 ET
Ionis expands eplontersen agreement with AstraZeneca to include exclusive rights in Latin America
2023-07-26 11:05 ET
Ionis to hold second quarter 2023 financial results webcast
2023-07-10 11:05 ET
Eplontersen continued to show improvement in ATTRv-PN through 85 weeks
2023-07-05 11:05 ET
Ionis to present at upcoming investor conference
2023-06-30 20:08 ET
New data highlight potential benefit of SPINRAZA® (nusinersen) in infants and toddlers with unmet medical needs after gene therapy
2023-06-08 05:09 ET
Ionis prices private placement of convertible senior notes
2023-06-06 20:01 ET
Ionis announces proposed private placement of convertible notes
2023-06-01 11:05 ET
Ionis announces positive donidalorsen late-stage clinical progress in HAE
2023-05-10 11:05 ET
Ionis to host 2023 virtual Annual Meeting of Stockholders
2023-05-09 11:05 ET
Ionis to present at upcoming investor conferences
2023-05-03 11:00 ET
Ionis reports first quarter 2023 financial results
2023-04-25 23:10 ET
FDA approves QALSODY™ (tofersen) as the first treatment targeting a genetic cause of ALS
2023-04-24 11:00 ET
Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study through 66 weeks
2023-04-20 11:05 ET
Ionis to hold first quarter 2023 financial results webcast
2023-03-29 12:45 ET
New data presented at AD/PD™2023 show IONIS-MAPT Rx (BIIB080) substantially reduced tau protein in patients with early-stage Alzheimer's disease
2023-03-28 11:05 ET
Ionis to present at upcoming investor conferences
2023-03-27 06:00 ET
Ionis reports positive topline 66-week results of eplontersen Phase 3 study for patients with ATTRv-PN
2023-03-23 03:01 ET
Ionis accounces FDA advisory committee voted unanimously for a potential accelerated approval of tofersen for SOD1-ALS
2023-03-07 12:05 ET
Ionis announces FDA acceptance of New Drug Application for eplontersen for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)
2023-02-28 12:05 ET
Ionis to present at upcoming investor conferences
2023-02-22 12:01 ET
Ionis reports fourth quarter and full year 2022 financial results
2023-02-21 12:05 ET
Ionis announces new donidalorsen data and presentations at the 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting
2023-02-08 12:05 ET
Ionis to hold fourth quarter and full year 2022 financial results webcast
2023-02-01 14:05 ET
Ionis announces GSK has advanced bepirovirsen into Phase 3 development
2023-01-31 12:05 ET
Ionis receives FDA Fast Track designation for olezarsen in patients with familial chylomicronemia syndrome
2023-01-26 14:30 ET
Ionis Chief Scientific Officer C. Frank Bennett, Ph.D. to receive Rainwater Prize for Outstanding Innovation in Neurodegenerative Disease Research
2023-01-09 14:15 ET
Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness
2023-01-09 14:05 ET
Ionis and Royalty Pharma enter into royalty agreement for up to $1.1 billion to further advance Ionis' genetic medicines and commercial readiness
2023-01-04 12:05 ET
Ionis to present at 41st Annual J.P. Morgan Healthcare conference
2022-12-05 12:30 ET
Ionis announces European Medicines Agency accepts Marketing Authorization Application of tofersen to treat rare, genetic form of ALS
2022-11-14 11:05 ET
Ionis partners with Metagenomi to add gene editing to its broad technology platform
2022-11-13 18:01 ET
Ionis presents positive Phase 2 data from open label extension study of donidalorsen at 2022 ACAAI Annual Meeting
2022-11-10 12:05 ET
Ionis to present at upcoming investor conferences
2022-11-09 12:00 ET
Ionis reports third quarter financial results
2022-11-08 15:57 ET
Ionis announces positive data from GSK's Phase 2b clinical study of bepirovirsen
2022-11-07 12:05 ET
Ionis presents positive Phase 2 data in patients with IgA Nephropathy at American Society of Nephrology's Kidney Week 2022
2022-11-04 11:05 ET
Ionis announces positive results from fesomersen development program
2022-10-26 11:05 ET
Ionis to hold third quarter 2022 financial results webcast
2022-10-12 11:05 ET
Ionis announces plan for new manufacturing facility in Oceanside, Calif.
2022-09-23 06:25 ET
Ionis provides update on development program evaluating PCSK9 antisense medicine for the treatment of hypercholesterolemia
2022-09-07 06:30 ET
Ionis presents positive results from Phase 3 NEURO-TTRansform study at International Symposium on Amyloidosis
2022-08-30 11:05 ET
Ionis to present at upcoming investor conferences
2022-08-09 11:00 ET
Ionis reports second quarter financial results and recent business achievements
2022-07-28 11:05 ET
Ionis announces positive topline results from Phase 2b clinical study of fesomersen, a potential novel anti-thrombotic treatment
2022-07-27 11:05 ET
Ionis to hold second quarter 2022 financial results webcast
2022-07-26 11:30 ET
Ionis announces that FDA accepts New Drug Application and grants Priority Review of tofersen for a rare, genetic form of ALS
2022-07-20 11:05 ET
Ionis announces enrollment completion of Phase 3 Lp(a) HORIZON cardiovascular outcomes study of pelacarsen
2022-07-13 11:05 ET
Ionis to participate in virtual fireside chat at H.C. Wainwright 1st Annual Hereditary Angioedema Conference
2022-07-11 11:05 ET
Ionis partner licenses rare kidney disease treatment and will advance into Phase 3 clinical study
2022-06-25 13:05 ET
Ionis announces presentation of positive Phase 2b data for chronic hepatitis B treatment at the EASL International Liver Congress™
2022-06-21 06:00 ET
Ionis announces eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)
2022-06-13 11:05 ET
Ionis treatment for Angelman syndrome receives orphan drug and rare pediatric disease designations from U.S. FDA
2022-06-03 09:20 ET
Ionis partner Biogen announces that results from Phase 3 VALOR study and open-label extension of tofersen showed clinical benefit in SOD1-ALS patients
2022-05-12 11:05 ET
Ionis to present at RBC Capital Markets Global Healthcare Conference
2022-05-04 11:00 ET
Ionis reports first quarter financial results and recent business achievements
2022-05-02 11:05 ET
Ionis to host 2022 virtual Annual Meeting of Stockholders
2022-04-20 11:05 ET
Ionis to hold first quarter 2022 financial results webcast
2022-04-04 04:15 ET
Ionis announces positive data for ETESIAN Phase 2b study of antisense medicine targeting PCSK9 at 2022 American College of Cardiology Scientific Session
2022-03-28 11:30 ET
Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
2022-03-28 11:30 ET
Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
2022-03-21 11:05 ET
Ionis to present at upcoming investor conferences
2022-03-16 23:16 ET
Ionis announces publication of positive Phase 2 data for donidalorsen in New England Journal of Medicine
2022-03-07 12:05 ET
Ionis calls for applications for Janice Wiesman Young Investigator Grant Program
2022-03-01 12:05 ET
Ionis to present at the Cowen Annual Health Care Conference
2022-02-24 12:00 ET
Ionis reports fourth quarter and full year 2021 financial results and recent business achievements
2022-02-10 12:05 ET
Ionis to hold full year 2021 financial results webcast
2022-01-31 12:05 ET
Pfizer and Ionis announce discontinuation of vupanorsen clinical development program
2022-01-24 12:05 ET
Ionis announces eplontersen receives orphan drug designation from U.S. FDA
2022-01-19 12:05 ET
Ionis strengthens leadership team with appointments of Joseph Baroldi as chief business officer and Eric Bastings, M.D., as vice president, development strategy
2022-01-18 05:05 ET
Ionis' partner to evaluate tominersen for Huntington's disease in new Phase 2 trial
2022-01-05 12:05 ET
Ionis to present at 40th Annual J.P. Morgan Healthcare conference
2022-01-04 12:34 ET
Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
2022-01-04 12:30 ET
Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
2021-12-29 07:00 ET
Ionis and AstraZeneca close deal to develop and commercialize eplontersen
2021-12-07 07:00 ET
Ionis and AstraZeneca to develop and commercialize eplontersen
2021-12-02 20:03 ET
Ionis to hold virtual investor day event
2021-11-24 11:30 ET
Ionis announces that Pfizer reports topline results from Phase 2b clinical study of vupanorsen
2021-11-18 18:30 ET
Ionis initiates Phase 3 clinical program of donidalorsen in patients with hereditary angioedema
2021-11-12 12:05 ET
Ionis' antisense therapies to be featured at the American Heart Association (AHA) Scientific Sessions 2021
2021-11-09 12:05 ET
Ionis to present at upcoming virtual investor conferences
2021-11-07 12:05 ET
Phase 2 study results of Ionis' novel antisense treatment for hereditary angioedema to be presented at ACAAI annual meeting
2021-11-03 11:00 ET
Ionis reports third quarter 2021 financial results and recent business achievements
2021-11-02 11:05 ET
Ionis initiates pivotal Phase 3 clinical study of olezarsen in patients with severe hypertriglyceridemia
2021-10-20 11:05 ET
Ionis to hold third quarter 2021 financial results webcast
2021-10-17 20:20 ET
Ionis' partner Biogen provides update on tofersen Phase 3 VALOR study in SOD1-ALS
2021-09-03 11:05 ET
Ionis to host ATTR symposium highlighting CARDIO-TTRansform Study at 3rd European ATTR Amyloidosis meeting
2021-09-02 11:05 ET
Ionis to present at upcoming virtual investor conferences
2021-07-29 11:05 ET
Ionis completes enrollment in pivotal NEURO-TTRansform study of eplontersen
2021-07-26 20:35 ET
Biogen and Ionis report positive topline clinical data on investigational Alzheimer's disease treatment at AAIC
2021-07-21 11:05 ET
Ionis to hold second quarter 2021 financial results webcast
2021-06-14 20:05 ET
Ionis' Chief Scientific Officer C. Frank Bennett, Ph.D., receives Gabbay Award in Biotechnology and Medicine
2021-06-10 22:05 ET
Ionis' antisense therapies in ATTR amyloidosis to be featured at 2021 PNS Annual Meeting
2021-06-02 23:59 ET
Ionis announces changes to its board of directors at annual meeting of stockholders
2021-05-26 11:05 ET
Ionis to present at upcoming investor conferences
2021-05-06 11:05 ET
Ionis to present at upcoming investor conferences
2021-05-05 20:05 ET
Ionis to host 2021 virtual annual meeting of stockholders
2021-05-05 11:00 ET
Ionis reports first quarter 2021 financial results and recent business achievements
2021-04-21 11:05 ET
Ionis to hold first quarter 2021 financial results webcast
2021-04-20 11:05 ET
Ionis initiates pivotal clinical study of novel antisense medicine to treat patients with Alexander disease
2021-04-19 11:30 ET
Biogen Advances Leading Research in Spinal Muscular Atrophy (SMA) with New Data at AAN 2021 Exploring Opportunities to Improve Outcomes for Patients
2021-04-08 11:05 ET
Ionis prices private placement of convertible senior notes
2021-04-06 20:36 ET
Ionis announces proposed private placement of convertible notes
2021-04-05 11:05 ET
Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS
2021-03-29 11:05 ET
Ionis reports positive topline Phase 2 study results of its novel antisense treatment for hereditary angioedema
2021-03-26 11:05 ET
Ionis to present at upcoming investor conferences
2021-03-22 20:01 ET
Ionis' partner provides update on clinical studies evaluating tominersen (IONIS-HTT Rx)
2021-03-08 13:05 ET
TRACON Pharmaceuticals Announces Appointment of Lisa Johnson-Pratt, M.D., to its Board of Directors
2021-03-01 12:05 ET
Ionis establishes new grant program to advance research and understanding of transthyretin amyloidosis
2021-02-24 12:00 ET
Ionis reports fourth quarter and full year 2020 financial results and recent business achievements
2021-02-19 12:05 ET
Ionis to present at upcoming investor conferences
2021-02-11 12:05 ET
Ionis to hold 2020 financial results webcast
2021-01-07 22:30 ET
Ionis appoints Eugene Schneider, M.D., as executive vice president and chief clinical development officer
2021-01-05 12:05 ET
Ionis to present at 39th Annual J.P. Morgan Healthcare Conference
2020-12-17 23:30 ET
Stanley T. Crooke, Ph.D., M.D, to retire from Ionis to focus on his scientific interests and n-Lorem Foundation
2020-12-09 02:15 ET
Ionis highlights achievements, commercial strategy and technology advancements at Investor Day
2020-12-02 12:05 ET
Ionis to participate in virtual fireside chat at BMO 2020 Growth and ESG conference
2020-12-01 22:10 ET
Ionis announces initiation of the global Phase 3 BALANCE study for AKCEA-APOCIII-LRX in patients with familial chylomicronemia syndrome
2020-12-01 12:05 ET
Ionis to hold virtual investor day event
2020-11-30 22:15 ET
Ionis announces AstraZeneca's initiation of the Phase 2b clinical study of its antisense medicine targeting PCSK9 to lower LDL-cholesterol
2020-11-23 22:15 ET
Ionis announces third investigational antisense medicine to treat nonalcoholic steatohepatitis (NASH) enters development
2020-11-13 12:05 ET
Promising new data for Ionis' antisense medicine targeting PCSK9 presented at American Heart Association (AHA) Scientific Sessions 2020
2020-11-12 12:05 ET
Ionis' pioneering antisense technology to be featured in multiple presentations at American Heart Association (AHA) Scientific Sessions 2020
2020-11-10 12:05 ET
Ionis' antisense technology to be featured during virtual RNA at the Bench and Bedside II Conference
2020-11-09 12:05 ET
Ionis to present at upcoming virtual investor conferences
2020-11-09 08:00 ET
WAYLIVRA▼® (volanesorsen), the First and Only Therapy for Familial Chylomicronaemia Syndrome, an Ultra-Rare and Life-Threatening Condition, to Be Available on the NHS in Scotland
2020-11-06 08:00 ET
Ionis and Akcea Recognize FCS Awareness Day With Global Community Efforts to Celebrate Unsung Heroes
2020-11-04 12:00 ET
Ionis reports third quarter 2020 financial results and recent business achievements
2020-11-03 23:00 ET
Ionis and Akcea announce that Pfizer has initiated a Phase 2b clinical study of vupanorsen (AKCEA-ANGPTL3-LRx)
2020-10-30 11:00 ET
Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology Product
2020-10-22 11:05 ET
Ionis' third novel antisense medicine for ALS, its first designed to treat a broad ALS population, begins clinical trial
2020-10-21 11:05 ET
Ionis to hold third quarter 2020 financial results webcast
2020-10-15 11:05 ET
Ionis antisense medicine being evaluated in an investigator-initiated clinical study of COVID-19 patients in Brazil
2020-10-13 11:05 ET
/C O R R E C T I O N -- Ionis Pharmaceuticals, Inc./
2020-10-12 13:00 ET
Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics
2020-10-01 20:05 ET
Ionis Chief Scientific Officer Frank Bennett receives Lifetime Achievement Award from Oligonucleotide Therapeutics Society
2020-10-01 10:00 ET
Ionis and Genuity Science announce agreement designed to rapidly translate genomic insights into therapeutics
2020-09-30 20:05 ET
Ionis treatment for Alexander disease receives orphan drug designation from U.S. FDA
2020-09-18 07:00 ET
WAYLIVRA▼® (volanesorsen), the First and Only Therapy for FCS, an Ultra-Rare and Life-Threatening Condition, to Be Available on the NHS in England
2020-09-03 11:05 ET
Ionis to present at upcoming virtual investor conferences
2020-09-02 21:10 ET
New England Journal of Medicine publishes study results evaluating Ionis antisense therapy in treatment of patients with hereditary angioedema
2020-08-31 10:55 ET
Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics
2020-08-29 08:00 ET
Positive Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L(Rx)) Presented at ESC Congress 2020
2020-08-29 07:30 ET
Positive Phase 2 Clinical Data of AKCEA-APOCIII-L(Rx) Presented at ESC Congress 2020
2020-08-26 11:05 ET
Ionis Pharmaceuticals to hold cardio-renal franchise webcast
2020-08-24 11:00 ET
Akcea and Ionis to Present Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L (Rx) ) at ESC Congress 2020
2020-08-18 11:00 ET
Akcea and Ionis to Present Phase 2 Results of AKCEA-APOCIII-L(Rx) in Late-Breaking Presentation at ESC Congress 2020
2020-08-13 11:00 ET
Akcea Announces New Pricing and Reimbursement of WAYLIVRA® (volanesorsen) in Germany
2020-08-05 11:00 ET
Ionis reports second quarter 2020 financial results and recent business achievements
2020-08-04 20:05 ET
Akcea Reports Financial Results and Highlights for Second Quarter 2020
2020-07-22 11:05 ET
Ionis Pharmaceuticals to hold second quarter 2020 financial results webcast
2020-07-22 11:00 ET
Akcea Announces Approval for Reimbursement of TEGSEDI® (inotersen) in Austria for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy
2020-07-21 11:00 ET
Akcea Therapeutics to Hold Second Quarter 2020 Financial Results Webcast
2020-07-20 11:00 ET
Akcea Appoints New Senior Vice President, Global Medical Affairs
2020-07-09 11:00 ET
Akcea Announces Appointment of New Chief Medical Officer
2020-07-07 11:05 ET
Ionis Pharmaceuticals to hold neurology franchise webcast
2020-06-29 11:00 ET
Akcea Appoints Tracy Palmer Berns as Chief Compliance Officer
2020-06-17 11:00 ET
Akcea Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
2020-06-09 11:00 ET
Akcea Appoints New Senior Vice President, Business Development and Corporate Strategy
2020-06-08 11:00 ET
Akcea announces approval for reimbursement of TEGSEDI® (inotersen) in Italy for treatment of hereditary transthyretin amyloidosis with polyneuropathy
2020-06-05 11:05 ET
Ionis Pharmaceuticals to present at upcoming virtual investor conferences
2020-06-01 11:00 ET
Akcea announces approval for reimbursement of TEGSEDI® (inotersen) in Portugal for treatment of hereditary transthyretin amyloidosis with polyneuropathy
2020-05-28 20:05 ET
Ionis Pharmaceuticals to host 2020 virtual annual meeting of stockholders
2020-05-18 11:00 ET
Akcea Announces Appointment of New Chief Financial Officer
2020-05-14 20:05 ET
Akcea Announces Approval for Reimbursement of TEGSEDI® (inotersen) in Spain for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy
2020-05-07 11:00 ET
Akcea Expands Leadership Team with Appointment of Carla Poulson as Senior Vice President and Chief Human Resources Officer
2020-05-06 11:00 ET
Ionis reports first quarter 2020 financial results and recent business achievements
2020-05-05 20:05 ET
Akcea Reports Financial Results and Highlights for First Quarter 2020
2020-05-01 11:05 ET
Ionis Pharmaceuticals to host 2020 virtual annual meeting of stockholders
2020-04-22 11:05 ET
Ionis Pharmaceuticals to hold first quarter 2020 financial results webcast
2020-04-21 11:00 ET
Akcea Therapeutics to Hold First Quarter 2020 Financial Results Webcast
2020-04-20 11:05 ET
Ionis and partner announce enrollment completion of global Phase 3 GENERATION HD1 study for Huntington's disease
2020-04-08 11:05 ET
Ionis establishes $25,000 scholarship to help ALS patients in greater San Diego area participate in physical and mental wellness programs
2020-04-07 11:05 ET
Ionis Pharmaceuticals to present at upcoming investor conferences
2020-03-24 11:00 ET
Akcea Therapeutics Announces Appointment of Dr. Damien McDevitt as CEO
2020-03-11 11:00 ET
Dr. Lisa Johnson-Pratt Joins Akcea Therapeutics as Senior Vice President, New Product Strategy; Joshua Patterson promoted to General Counsel, adding to the company’s leadership team
2020-02-28 12:00 ET
Akcea Supports Rare Disease Day 2020 and Global Efforts to “Reframe Rare”
2020-02-27 12:05 ET
Ionis Pharmaceuticals to present at upcoming investor conferences
2020-02-26 12:00 ET
Ionis provides fourth quarter and full year 2019 financial results
2020-02-26 12:00 ET
Akcea Therapeutics to Present at the Cowen 40th Annual Health Care Conference
2020-02-25 21:05 ET
Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End 2019
2020-02-19 12:05 ET
Ionis Pharmaceuticals to hold 2019 financial results webcast
2020-02-18 12:00 ET
Akcea Therapeutics to Hold Fourth Quarter and Full Year 2019 Financial Results Webcast
2020-02-13 12:00 ET
Akcea Expands Board of Directors with Appointment of Dr. Amber Salzman
2020-02-11 12:05 ET
Ionis treatment for Alexander disease granted orphan drug status from EMA
2020-01-28 21:05 ET
Akcea and Ionis report positive topline phase 2 study results of AKCEA-ANGPTL3-LRx
2020-01-22 12:05 ET
Akcea and Ionis report positive topline Phase 2 results of AKCEA-APOCIII-L Rx
2020-01-10 12:00 ET
Akcea and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with TTR-mediated Amyloid Cardiomyopathy
2020-01-07 17:14 ET
Ionis' neurological franchise marks year of achievement
2020-01-06 12:05 ET
Ionis Pharmaceuticals to present at 38th annual J.P. Morgan Healthcare Conference
2020-01-02 13:00 ET
New England Journal of Medicine Publishes Results from Phase 2 Study of AKCEA-APO(a)-LRx in Patients with Lp(a)-driven Cardiovascular Disease
2019-12-19 03:03 ET
Akcea Retains Rights to AKCEA-APOCIII-LRx
2019-12-16 12:00 ET
Akcea Therapeutics Announces New Appointments to its Board of Directors
2019-12-12 12:05 ET
Ionis Pharmaceuticals announces private placement of $507.5 million principal amount of 0.125% convertible senior notes due 2024
2019-12-04 12:00 ET
Akcea Announces Appointment of New Chief Operating Officer
2019-12-02 12:05 ET
Ionis Pharmaceuticals to hold technology webcast
2019-11-25 12:00 ET
Akcea and Ionis Announce Initiation of NEURO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with Polyneuropathy Driven by Hereditary TTR Amyloidosis
2019-11-19 21:05 ET
Akcea and Ionis Announce Closing of Licensing Agreement with Pfizer Inc. for Investigative Antisense Therapy AKCEA-ANGPTL3-L(Rx)
2019-11-18 17:00 ET
Antisense Therapeutics Announces Additional preliminary data from the ATL1102 Phase II DMD trial presented at the 2019 Action Duchenne International Conference
2019-11-13 12:00 ET
Akcea Therapeutics to Present at Upcoming Investor Conferences
2019-11-12 12:05 ET
Ionis Pharmaceuticals to present at upcoming investor conferences
2019-11-05 21:05 ET
Akcea Reports Financial Results and Highlights for Third Quarter 2019
2019-11-01 11:00 ET
Akcea Recognizes Landmark Year for Familial Chylomicronemia Syndrome (FCS) Community with Commemoration of 2nd Annual FCS Awareness Day
2019-10-28 11:05 ET
Bench to bedside strategies demonstrate Ionis' foremost expertise in RNA-targeted therapeutics at DIA/FDA Oligonucleotide Conference
2019-10-23 11:05 ET
Ionis Chairman and CEO Stanley T. Crooke, M.D., Ph.D. to receive Massry Prize for contributions to biomedical sciences
2019-10-23 11:00 ET
Akcea Announces Appointment of New Chief Commercial Officer
2019-10-22 11:05 ET
Ionis Pharmaceuticals to hold third quarter 2019 financial results webcast
2019-10-22 11:00 ET
Akcea Therapeutics to Hold Third Quarter 2019 Financial Results Webcast
2019-10-10 11:05 ET
Ionis' leadership in RNA-targeted therapeutics recognized at the Oligonucleotide Therapeutics Society annual meeting
2019-10-09 10:50 ET
Ionis' Factor XI anti-thrombotic medicine advances with Bayer following positive clinical results
2019-10-07 10:50 ET
Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-L(Rx)
2019-09-23 11:00 ET
Akcea Announces CEO Transition and Elects Two New Board Members
2019-09-18 02:23 ET
Positive preliminary results from ATL1102 for DMD Phase II trial
2019-09-16 11:00 ET
Positive Phase 1 Results of AKCEA-TTR-LRx Presented at the Heart Failure Society of America Annual Meeting
2019-08-28 11:05 ET
Ionis Pharmaceuticals to present at upcoming investor conferences
2019-08-27 11:05 ET
Ionis licenses hepatitis B program to GSK
2019-08-07 11:00 ET
Ionis Reports Second Quarter 2019 Financial Results
2019-07-30 11:05 ET
Ionis Pharmaceuticals to hold second quarter 2019 financial results webcast
2019-06-18 11:05 ET
Ionis Pharmaceuticals to present at the BMO Prescription for Success Healthcare Conference
2019-06-12 20:05 ET
Ionis announces appointment of Joan E. Herman to its board of directors
2019-06-06 11:05 ET
Ionis Pharmaceuticals to provide corporate update and 30-year retrospective at its 2019 Annual Meeting of Stockholders
2019-05-06 11:05 ET
Ionis launches new corporate brand that reflects company's industry-leading innovation and unique culture of saying "yes" to patients
2019-05-01 11:05 ET
Positive clinical data at AAN 2019 reinforces Ionis' commitment to delivering life-changing medicines to patients with neurological diseases
2019-04-25 11:05 ET
Ionis Pharmaceuticals to hold first quarter 2019 financial results webcast
2019-04-08 20:05 ET
Ionis Pharmaceuticals to Provide Corporate Update at 2019 Annual Meeting of Stockholders
2018-12-20 12:20 ET
New Research: Key Drivers of Growth for Baxter International, Sempra Energy, Nielsen Holdings Plc, ARRIS International plc, Ionis Pharmaceuticals, and KB Home — Factors of Influence, Major Initiatives and Sustained Production

SEC forms

Show financial reports only

SEC form 8
2025-04-30 00:00 ET
Ionis Pharmaceuticals published news for 2025 q1
SEC form 8
2025-04-30 00:00 ET
Ionis Pharmaceuticals published news for 2025 q1
SEC form 10
2025-04-30 00:00 ET
Ionis Pharmaceuticals reported for 2025 q1
SEC form 8
2025-02-19 00:00 ET
Ionis Pharmaceuticals reported for 2024 q4
SEC form 8
2025-02-19 00:00 ET
Ionis Pharmaceuticals published news for 2024 q4
SEC form 10
2025-02-19 00:00 ET
Ionis Pharmaceuticals reported for 2024 q4
SEC form 10
2024-11-06 16:06 ET
Ionis Pharmaceuticals published news for 2024 q3
SEC form 8
2024-11-06 11:15 ET
Ionis Pharmaceuticals published news for 2024 q3
SEC form 8
2024-11-06 11:15 ET
Ionis Pharmaceuticals published news for 2024 q3
SEC form 10
2024-08-01 16:57 ET
Ionis Pharmaceuticals published news for 2024 q2
SEC form 8
2024-08-01 11:15 ET
Ionis Pharmaceuticals reported for 2024 q2
SEC form 8
2024-08-01 11:15 ET
Ionis Pharmaceuticals published news for 2024 q2
SEC form 10
2024-08-01 00:00 ET
Ionis Pharmaceuticals published news for 2024 q2
SEC form 10
2024-05-07 15:55 ET
Ionis Pharmaceuticals published news for 2024 q1
SEC form 8
2024-05-07 11:15 ET
Ionis Pharmaceuticals published news for 2024 q1
SEC form 8
2024-05-07 11:15 ET
Ionis Pharmaceuticals reported for 2024 q1
SEC form 10
2024-05-07 00:00 ET
Ionis Pharmaceuticals published news for 2024 q1
SEC form 10
2024-02-21 16:38 ET
Ionis Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-21 11:17 ET
Ionis Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-21 11:17 ET
Ionis Pharmaceuticals reported for 2023 q4
SEC form 10
2024-02-21 00:00 ET
Ionis Pharmaceuticals published news for 2023 q4
SEC form 10
2023-11-02 14:43 ET
Ionis Pharmaceuticals published news for 2023 q3
SEC form 8
2023-11-02 11:15 ET
Ionis Pharmaceuticals reported for 2023 q3
SEC form 10
2023-11-02 00:00 ET
Ionis Pharmaceuticals published news for 2023 q3
SEC form 10
2023-08-09 13:50 ET
Ionis Pharmaceuticals published news for 2023 q2
SEC form 6
2023-08-09 11:15 ET
Ionis Pharmaceuticals reported for 2023 q2
SEC form 10
2023-08-09 00:00 ET
Ionis Pharmaceuticals published news for 2023 q2
SEC form 8
2023-08-09 00:00 ET
Ionis Pharmaceuticals published news for 2023 q2
SEC form 6
2023-08-04 16:30 ET
Ionis Pharmaceuticals published news for 2023 q2
SEC form 6
2023-08-03 16:30 ET
Ionis Pharmaceuticals published news for 2023 q2
SEC form 6
2023-07-10 07:00 ET
Ionis Pharmaceuticals published news for 2023 q2
SEC form 6
2023-06-12 16:03 ET
Ionis Pharmaceuticals published news for 2023 q1
SEC form 6
2023-06-06 16:12 ET
Ionis Pharmaceuticals published news for 2023 q1
SEC form 6
2023-06-05 10:56 ET
Ionis Pharmaceuticals published news for 2023 q1
SEC form 10
2023-05-03 00:00 ET
Ionis Pharmaceuticals published news for 2023 q1
SEC form 8
2023-05-03 00:00 ET
Ionis Pharmaceuticals reported for 2023 q1
SEC form 6
2023-03-27 06:01 ET
Ionis Pharmaceuticals published news for 2022 q4
SEC form 10
2023-02-22 16:39 ET
Ionis Pharmaceuticals reported for 2022 q4
SEC form 6
2023-02-22 11:15 ET
Ionis Pharmaceuticals published news for 2022 q4
SEC form 10
2023-02-22 00:00 ET
Ionis Pharmaceuticals reported for 2022 q4
SEC form 8
2023-02-22 00:00 ET
Ionis Pharmaceuticals reported for 2022 q4
SEC form 6
2023-01-09 09:10 ET
Ionis Pharmaceuticals published news for 2022 q4
SEC form 6
2022-11-14 06:10 ET
Ionis Pharmaceuticals published news for 2022 q3
SEC form 10
2022-11-09 14:38 ET
Ionis Pharmaceuticals reported for 2022 q3
SEC form 6
2022-11-09 11:15 ET
Ionis Pharmaceuticals published news for 2022 q3
SEC form 8
2022-11-09 00:00 ET
Ionis Pharmaceuticals reported for 2022 q3
SEC form 10
2022-11-09 00:00 ET
Ionis Pharmaceuticals reported for 2022 q3
SEC form 6
2022-11-04 07:05 ET
Ionis Pharmaceuticals published news for 2022 q3
SEC form 6
2022-10-24 10:00 ET
Ionis Pharmaceuticals published news for 2022 q3
SEC form 6
2022-10-12 07:15 ET
Ionis Pharmaceuticals published news for 2022 q3
SEC form 10
2022-08-09 15:56 ET
Ionis Pharmaceuticals reported for 2022 q2
SEC form 6
2022-08-09 11:15 ET
Ionis Pharmaceuticals published news for 2022 q2
SEC form 8
2022-08-09 00:00 ET
Ionis Pharmaceuticals reported for 2022 q2
SEC form 10
2022-08-09 00:00 ET
Ionis Pharmaceuticals reported for 2022 q2
SEC form 6
2022-07-28 06:02 ET
Ionis Pharmaceuticals published news for 2022 q2
SEC form 6
2022-07-19 06:02 ET
Ionis Pharmaceuticals published news for 2022 q2
SEC form 6
2022-07-15 20:16 ET
Ionis Pharmaceuticals published news for 2022 q2
SEC form 6
2022-07-11 10:14 ET
Ionis Pharmaceuticals published news for 2022 q2
SEC form 6
2022-06-21 06:03 ET
Ionis Pharmaceuticals published news for 2022 q1
SEC form 6
2022-06-06 16:00 ET
Ionis Pharmaceuticals published news for 2022 q1
SEC form 10
2022-05-04 17:11 ET
Ionis Pharmaceuticals reported for 2022 q1
SEC form 6
2022-05-04 11:15 ET
Ionis Pharmaceuticals published news for 2022 q1
SEC form 10
2022-05-04 00:00 ET
Ionis Pharmaceuticals reported for 2022 q1
SEC form 8
2022-05-04 00:00 ET
Ionis Pharmaceuticals reported for 2022 q1
SEC form 6
2022-04-20 12:22 ET
Ionis Pharmaceuticals published news for 2022 q1
SEC form 6
2022-03-18 18:03 ET
Ionis Pharmaceuticals published news for 2021 q4
SEC form 10
2022-02-25 00:00 ET
Ionis Pharmaceuticals published news for 2021 q4
SEC form 10
2022-02-24 17:38 ET
Ionis Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-24 11:15 ET
Ionis Pharmaceuticals published news for 2021 q4
SEC form 8
2022-02-24 00:00 ET
Ionis Pharmaceuticals published news for 2021 q4
SEC form 6
2022-01-31 07:32 ET
Ionis Pharmaceuticals published news for 2021 q4
SEC form 6
2021-12-07 06:02 ET
Ionis Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-26 16:05 ET
Ionis Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-24 09:29 ET
Ionis Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-03 15:37 ET
Ionis Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-03 11:15 ET
Ionis Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-03 00:00 ET
Ionis Pharmaceuticals published news for 2021 q3
SEC form 8
2021-11-03 00:00 ET
Ionis Pharmaceuticals published news for 2021 q3
SEC form 6
2021-10-18 14:31 ET
Ionis Pharmaceuticals published news for 2021 q3
SEC form 10
2021-08-04 15:20 ET
Ionis Pharmaceuticals published news for 2021 q2
SEC form 6
2021-08-04 11:15 ET
Ionis Pharmaceuticals published news for 2021 q2
SEC form 8
2021-08-04 00:00 ET
Ionis Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-04 00:00 ET
Ionis Pharmaceuticals published news for 2021 q2
SEC form 6
2021-06-04 16:43 ET
Ionis Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-05 14:58 ET
Ionis Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-05 11:16 ET
Ionis Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-05 00:00 ET
Ionis Pharmaceuticals published news for 2021 q1
SEC form 8
2021-05-05 00:00 ET
Ionis Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-23 06:08 ET
Ionis Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-12 21:13 ET
Ionis Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-06 07:00 ET
Ionis Pharmaceuticals published news for 2021 q1
SEC form 6
2021-03-29 10:23 ET
Ionis Pharmaceuticals published news for 2020 q4
SEC form 6
2021-03-22 19:40 ET
Ionis Pharmaceuticals published news for 2020 q4
SEC form 10
2021-02-24 15:34 ET
Ionis Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-24 08:45 ET
Ionis Pharmaceuticals published news for 2020 q4
SEC form 6
2020-12-17 21:21 ET
Ionis Pharmaceuticals published news for 2020 q3
SEC form 6
2020-12-09 06:13 ET
Ionis Pharmaceuticals published news for 2020 q3
SEC form 10
2020-11-04 17:01 ET
Ionis Pharmaceuticals published news for 2020 q3
SEC form 6
2020-11-04 11:15 ET
Ionis Pharmaceuticals published news for 2020 q3
SEC form 6
2020-10-13 08:43 ET
Ionis Pharmaceuticals published news for 2020 q3